Taking Gene-Silencing to the DNA Level
Oncogenuity is developing novel oligonucleotides for the treatment of genetically driven diseases, including cancers and coronaviruses by targeting gene-silencing at the DNA level.
What Sets Us ApartOur pipeline of targeted therapeutics against genetic mutations is a result of combining gene sequence data with rigorous statistical, mechanical and molecular modeling.
View PipelineOur proprietary platform produces oligomers, now known as “ONCOlogues,” that are capable of binding gene sequences 1,000 times more effectively than complementary native DNA.
Explore Our Technology